Literature DB >> 19076859

CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Partha Mukhopadhyay1, Rajesh Mohanraj, Sándor Bátkai, Pál Pacher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19076859      PMCID： PMC2669829          DOI： 10.1111/j.1751-7133.2008.00016.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN： 1527-5299


× No keyword cloud information.
  40 in total

1.  Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

Authors:  Partha Mukhopadhyay; Sándor Bátkai; Mohanraj Rajesh; Nora Czifra; Judith Harvey-White; György Haskó; Zsuzsanna Zsengeller; Norma P Gerard; Lucas Liaudet; George Kunos; Pál Pacher
Journal:  J Am Coll Cardiol       Date:  2007-07-23       Impact factor: 24.094

2.  Effects of AM281, a cannabinoid antagonist, on circulatory deterioration and cytokine production in an endotoxin shock model: comparison with norepinephrine.

Authors:  Yuji Kadoi; Fumio Goto
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

3.  CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; John W Huffman; Anna Csiszar; Zoltan Ungvari; Ken Mackie; Subroto Chatterjee; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-27       Impact factor: 4.733

Review 4.  PARP inhibitors and heart failure--translational medicine caught in the act.

Authors:  George W Booz
Journal:  Congest Heart Fail       Date:  2007 Mar-Apr

5.  Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.

Authors:  Clemens Sommer; Markus Schomacher; Christian Berger; Katharina Kuhnert; Harald D Müller; Stefan Schwab; Wolf-Rüdiger Schäbitz
Journal:  Acta Neuropathol       Date:  2006-07-27       Impact factor: 17.088

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

8.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

Review 9.  The endocannabinoid system: a new target for the regulation of energy balance and metabolism.

Authors:  Jean-Pierre Després
Journal:  Crit Pathw Cardiol       Date:  2007-06

10.  Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

Authors:  Magali Gary-Bobo; Ghizlane Elachouri; Jean François Gallas; Philip Janiak; Pietro Marini; Christine Ravinet-Trillou; Michèle Chabbert; Noël Cruccioli; Christian Pfersdorff; Claude Roque; Michèle Arnone; Tiziano Croci; Philippe Soubrié; Florence Oury-Donat; Jean Pierre Maffrand; Bernard Scatton; Frederic Lacheretz; Gérard Le Fur; Jean Marc Herbert; Mohammed Bensaid
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425
View more
  10 in total

1.  Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.

Authors:  Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Nicholas Seneca; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-24       Impact factor: 9.236

Review 2.  Endocannabinoids and cardiac contractile function: pathophysiological implications.

Authors:  Sándor Bátkai; Pál Pacher
Journal:  Pharmacol Res       Date:  2009-08       Impact factor: 7.658

3.  Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase.

Authors:  Daniel R McDougle; Amogh Kambalyal; Daryl D Meling; Aditi Das
Journal:  J Pharmacol Exp Ther       Date:  2014-10-02       Impact factor: 4.030

4.  Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes: A Systematic Review.

Authors:  Divya Ravi; Mehrnaz Ghasemiesfe; Deborah Korenstein; Thomas Cascino; Salomeh Keyhani
Journal:  Ann Intern Med       Date:  2018-01-23       Impact factor: 25.391

Review 5.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

6.  Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy.

Authors:  Fabio A Iannotti; Ester Pagano; Ombretta Guardiola; Simone Adinolfi; Valentina Saccone; Silvia Consalvi; Fabiana Piscitelli; Elisabetta Gazzerro; Giuseppe Busetto; Diego Carrella; Raffaele Capasso; Pier Lorenzo Puri; Gabriella Minchiotti; Vincenzo Di Marzo
Journal:  Nat Commun       Date:  2018-09-27       Impact factor: 14.919

7.  Application of medical cannabis in unstable angina and coronary artery disease: A case report.

Authors:  Brian L Shaffer; Garrison M Davis; Marc A Incitti; Brian J Piper; Brian V Entler
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

Review 8.  Cannabinoids, the Heart of the Matter.

Authors:  Naghum Alfulaij; Franziska Meiners; Justin Michalek; Andrea L Small-Howard; Helen C Turner; Alexander J Stokes
Journal:  J Am Heart Assoc       Date:  2018-07-13       Impact factor: 5.501

9.  Potential Implications of Rimonabant on Age-Related Oxidative Stress and Inflammation.

Authors:  Renáta Szabó; Zsuzsanna Szabó; Denise Börzsei; Alexandra Hoffmann; Zelma Nadin Lesi; Patrícia Pálszabó; Andrea Pálszabó; Szabolcs Dvorácskó; Rudolf Gesztelyi; Krisztina Kupai; Dániel Priksz; Béla Juhász; Anita Altmayer; Csaba Varga; Anikó Pósa
Journal:  Antioxidants (Basel)       Date:  2022-01-14

10.  Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study.

Authors:  Arsene Zongo; Cerina Lee; Jason R B Dyck; Jihane El-Mourad; Elaine Hyshka; John G Hanlon; Dean T Eurich
Journal:  BMC Cardiovasc Disord       Date:  2021-09-10       Impact factor: 2.298
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.